MENLO PARK, Calif.--(BUSINESS WIRE)--Avellino Labs, global biotechnology and genetic science innovators, announced the strategic addition of James (Jim) V. Mazzo to its board of directors. While Avellino Labs continues to expand its research scope and apply its technology across multiple specialties and diseases, the partnership will further anchor Avellino Lab's leadership in developing the science and setting the standard of genetic testing in ophthalmology.
With over 38 years of experience building and advancing world-class ophthalmic organizations, Mazzo joins the Avellino Labs Board of Directors as one of the industry's best-known and most respected leaders.
"Jim's [Mazzo] knowledge of the ophthalmic community underscores our mission to collaborate closely with eye care professionals to provide them with the solutions they need to best serve their patients." said Avellino Labs Chairman of the Board Gene Lee. "We believe his expertise will strengthen our efforts as we partner with clinical and scientific experts to advance the science of genetic testing and gene therapy in ophthalmology."
Mazzo is currently the Global President of Ophthalmic Devices at Carl Zeiss Meditec. He also serves on the ASCRS Governing Board, the AAO Foundation Advisory Board, and is an Executive Committee Member of the Medical Device Manufacturers Association (MDMA). Throughout his career, Mazzo has held various executive and board leadership roles at ophthalmic organizations, including Allergan, Advanced Medical Optics, Abbott, AcuFocus, Neurotech and AdvaMed.
"Avellino Labs is the future of personal medicine in ophthalmology," said Mazzo. "I'm looking forward to working alongside these visionaries, as well as ophthalmic and optometric providers, to create new opportunities for earlier detection of diseases, leading to greater treatment options and overall better patient care."
To learn more about Avellino Labs, visit avellino.com.
About Avellino Labs
Avellino Labs is a global leader in gene therapy and molecular diagnostics, and the pioneer in personalized medicine for eye care. Avellino Labs is pioneering CRISPR gene editing to manage and potentially cure inherited diseases. Avellino Labs continues to expand its diagnostics capabilities, building on the success of the world's first DNA test to confirm the presence of genetic indicators that are positively associated with corneal dystrophies, providing life-changing information for patient treatment decisions and follow up care. Avellino Labs is headquartered in Silicon Valley, California, with operations in Korea, Japan, China and the UK.
Avellino Labs was named a 2015 Technology Pioneer by the World Economic Forum based on its potential to impact global health.
To learn more, please visit http://www.avellino.com/ or follow us on Twitter @Avellinolab_USA.
